The grades of five life science stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
This week, PAREXEL International Corporation (PRXL) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Parexel International is a contract research and product launch organization. In Portfolio Grader’s specific subcategories of Earnings Growth, Equity and Margin Growth, PRXL also gets A’s. Shares of PRXL have increased 6.6% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PRXL stock.
Pacific Biosciences of California, Inc. (PACB) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Pacific Biosciences of California has developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. For more information, get Portfolio Grader’s complete analysis of PACB stock.
The rating of Furiex Pharmaceuticals, Inc. (FURX) moves up this week, rising from a C to a B. Furiex Pharmaceuticals is a drug development company. For more information, get Portfolio Grader’s complete analysis of FURX stock.
This is a strong week for Albany Molecular Research, Inc. (AMRI). The company’s rating climbs to B from the previous week’s C. Albany Molecular Research provides contract services to various pharmaceutical and biotechnology companies primarily in the United States, Europe, and Asia. For more information, get Portfolio Grader’s complete analysis of AMRI stock.
Affymetrix, Inc. (AFFX) earns an A this week, jumping up from last week’s grade of B. Affymetrix is involved in the development, manufacturing and sale of products and services for genetic analysis to the life science research and clinical healthcare markets. For more information, get Portfolio Grader’s complete analysis of AFFX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
